2.2.1	In vitro / physicochemical data

A literature search was carried out to collect available information on physicochemical properties of atazanavir. The obtained information from the literature is summarized in the table below and is used for model building.

| **Parameter**          | **Unit** | **Raltegravir literature**                                   | **Description**                                       |
| :--------------------- | -------- | ------------------------------------------------------------ | ----------------------------------------------------- |
| Molecular weight       | g/mol    | 704.9 ([drugbank.ca](# 5 References))                        | Molecular weight                                      |
| pK<sub>a</sub> (basic) |          | 4.7 ([Berlin 2015](# 5 References))                          | Acid dissociation constant                            |
| logP                   |          | 2.12 ([Hyland 2008](# 5 References))                         | Partition coefficient between octanol and water       |
| f<sub>u</sub>          |          | 0.14 ([US Food and Drug Administration 2002](# 5 References)) | Fraction unbound in human plasma                      |
| Solubililty in FaSSIF  | µg/mL    | 2.74 ([Berlin 2015](# 5 References))                         | Solubility in Fasted State Simulated Intestinal Fluid |
| Solubililty in FeSSIF  | µg/mL    | 4.13 ([Berlin 2015](# 5 References))                         | Solubility in Fed State Simulated Intestinal Fluid    |

### 2.2.2	Clinical data

A literature search was carried out to collect available PK data on atazanavir in healthy adults. 

The following publications were found and used for model building and evaluation:

| Publication                                            | Study description                                            |
| :----------------------------------------------------- | :----------------------------------------------------------- |
| [Acosta 2007](# 5 References)                          | 300 mg atazanavir BID, Period 1                              |
| [Agarwala 2003](# 5 References)                        | 400 mg atazanavir QD, Day 6                                  |
| [Agarwala 2005a](# 5 References)                       | 400 mg atazanavir QD, 400 mg AM                              |
| [Agarwala 2005b](# 5 References)                       | 400 mg atazanavir QD, 400 mg (Treatment A)                   |
| [Martin 2008](# 5 References)                          | 400 mg atazanavir QD, monotherapy                            |
| [Zhu 2010](# 5 References)                             | 300 mg atazanavir QD                                         |
| [Zhu 2011](# 5 References)                             | 400 mg atazanavir QD, 400 mg QPM and QAM                     |
| [US Food and Drug Administration 2002](# 5 References) | AI424-004 (p. 94): 400 mg atazanavir single dose (treatment A); AI424-014 (p. 77): 400 mg atazanavir single dose (young females & males); AI424-015 (p. 81): 400 mg atazanavir single dose (normal subjects); AI424-028 (p. 128): 200, 400, and 800 mg atazanavir QD (A-D Day6); AI424-029 (p. 47): 400 mg [<sup>14</sup>C]atazanavir single dose; AI424-040 (p. 64): 200, 400, and 800 mg atazanavir QD; AI424-056 (p. 134): 300 mg atazanavir QD (without ritonavir, Day 10); AI424-076 (p. 178): 400 and 800 mg atazanavir QD |

